|
Market Closed -
Nasdaq
23:00:00 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.46 USD | -4.42% |
|
+5.52% | +17.90% |
| 10-01 | Replimune Receives Approval to Launch Tudriqev in the US for Melanoma | MT |
| 10-01 | Replimune Group, Inc. Announces Tudriqev? Now Commercially Available in the United States for Advanced Melanoma | CI |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REPL | Delayed | |
CBOE
| REPL | Real-time | |
|
Deutsche Boerse AG
| 7R8 | Delayed | |
|
Börse Stuttgart
| 7R8 | Delayed | |
|
Boerse Muenchen
| 7R8 | Real-time | |
|
Tradegate
| 7R8 | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bullish | Bullish |
| Resistance | 12.06 | 15.98 | 15.5 |
| Spread/Res. | -4.98% | -28.29% | -26.06% |
| Spread/Supp. | +5.52% | +114.21% | +102.12% |
| Support | 10.86 | 5.35 | 5.67 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- REPL Stock
- Charts Replimune Group, Inc.
Select your edition
All financial news and data tailored to specific country editions
